To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning).
The purposes of this study are: 1. To reveal the genetic determinants of the treatment outcome of escitalopram in depressed patients (by using candidate gene approach and whole genome scanning) 2. To improve the success rate of escitalopram treatment response for depressed patients
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
202
Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
Samsung Medical Center
Kangnam, Seoul, South Korea
antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks
Time frame: 8 weeks
biological value at 0 week and 8 weeks
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.